We know that technology has had a tremendous on the medical field. And artificial intelligence (AI) is coming on strong. Today, we look at how AI aids drug operations.
“Recently, two AI drug design companies, Insilico Medicine and A2A Pharmaceuticals joined forces to bring to market a possible treatment for Duchenne muscular dystrophy (DMD) and other rare orphan diseases. Using AI to more rapidly discover optimal pre-clinical candidates may revolutionize the drug development process in the life sciences.”
“What AI can bring to the table is the ability to rapidly and accurately sort through massive amounts of data. This may very well revolutionize how competitive intelligence, drug discovery and stakeholder engagement take place as we know it. Among many functions that medical affairs is tasked with, an important one is stakeholder engagement with External Experts (EE) (formerly known as KOLs or Key Opinion Leaders). For Medical Science Liaisons (MSLs), who are the primary function engaging external stakeholders, there will likely be several changes.”
Click the image to read a lot more.